Cardiol Therapeutics Class Stock Probability of Future Stock Price Finishing Over 2.03

CRDL Stock  CAD 2.03  0.01  0.49%   
Cardiol Therapeutics' future price is the expected price of Cardiol Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Cardiol Therapeutics Class performance during a given time horizon utilizing its historical volatility. Check out Cardiol Therapeutics Backtesting, Cardiol Therapeutics Valuation, Cardiol Therapeutics Correlation, Cardiol Therapeutics Hype Analysis, Cardiol Therapeutics Volatility, Cardiol Therapeutics History as well as Cardiol Therapeutics Performance.
  
As of the 11th of December 2024, Price To Sales Ratio is likely to drop to 1,023. In addition to that, Price Earnings Ratio is likely to drop to -2.65. Please specify Cardiol Therapeutics' target price for which you would like Cardiol Therapeutics odds to be computed.

Cardiol Therapeutics Target Price Odds to finish over 2.03

The tendency of Cardiol Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.03 90 days 2.03 
over 95.99
Based on a normal probability distribution, the odds of Cardiol Therapeutics to move above the current price in 90 days from now is over 95.99 (This Cardiol Therapeutics Class probability density function shows the probability of Cardiol Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Cardiol Therapeutics has a beta of 1.0 suggesting Cardiol Therapeutics Class market returns are highly reactive to returns on the market. As the market goes up or down, Cardiol Therapeutics is expected to follow. Additionally Cardiol Therapeutics Class has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Cardiol Therapeutics Price Density   
       Price  

Predictive Modules for Cardiol Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cardiol Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.102.025.44
Details
Intrinsic
Valuation
LowRealHigh
0.091.715.13
Details
Naive
Forecast
LowNextHigh
0.042.215.63
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.1-0.1-0.1
Details

Cardiol Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Cardiol Therapeutics is not an exception. The market had few large corrections towards the Cardiol Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cardiol Therapeutics Class, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cardiol Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.55
β
Beta against Dow Jones1.00
σ
Overall volatility
0.32
Ir
Information ratio -0.15

Cardiol Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cardiol Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cardiol Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Cardiol Therapeutics generated a negative expected return over the last 90 days
Cardiol Therapeutics has high historical volatility and very poor performance
Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (28.13 M) with profit before overhead, payroll, taxes, and interest of 78.76 K.
Cardiol Therapeutics Class has accumulated about 59.47 M in cash with (25.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48.
Latest headline from news.google.com: Cardiol Therapeutics Shares Up 1.8 percent - Whats Next - MarketBeat

Cardiol Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cardiol Stock often depends not only on the future outlook of the current and potential Cardiol Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cardiol Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding64.5 M
Cash And Short Term Investments34.9 M

Cardiol Therapeutics Technical Analysis

Cardiol Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cardiol Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cardiol Therapeutics Class. In general, you should focus on analyzing Cardiol Stock price patterns and their correlations with different microeconomic environments and drivers.

Cardiol Therapeutics Predictive Forecast Models

Cardiol Therapeutics' time-series forecasting models is one of many Cardiol Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cardiol Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Cardiol Therapeutics

Checking the ongoing alerts about Cardiol Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cardiol Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cardiol Therapeutics generated a negative expected return over the last 90 days
Cardiol Therapeutics has high historical volatility and very poor performance
Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (28.13 M) with profit before overhead, payroll, taxes, and interest of 78.76 K.
Cardiol Therapeutics Class has accumulated about 59.47 M in cash with (25.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48.
Latest headline from news.google.com: Cardiol Therapeutics Shares Up 1.8 percent - Whats Next - MarketBeat
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.